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Abstract The objective of this study is to assess the effective-
ness and safety of TNF-α blockers in a group of early psoriatic
arthritis (PsA) patients with an unsatisfactory response to
previous conventional treatment consecutively enrolled in five
Italian centres. A 24-week open-label trial was carried out in
consecutive early PsA patients classified according to the
CASPAR criteria, with unsatisfactory response to previous
treatments and with a DAS28 threshold as ≥3.2, seen at the
outpatient clinics of eachcentre.Exclusioncriteria wereprevious
usage of TNF-α blockers and a disease duration >12 months.
T h ec h o i c eo fa n yo ft h et h r e eT N F - α blockers was decided by
the expert’s opinion, without any restriction. Effectiveness was
considered as an improvement of DAS28 at 12 and 24 weeks of
treatment. Secondary endpoints were an improvement of TJC,
SWJ, HAQ score and PASI score. Changes from baseline to the
12- and 24-week follow-up assessments were analysed using the
Wilcoxon paired sign rank test. Twenty-nine patients (14 males,
15 females, median age 37 years, range 20–65 years) were
enrolled. A statistical improvement of the DAS28 was observed
at 12 and 24 weeks from baseline (p<0.001). Secondary
endpoints also confirmed the effectiveness of the TNF-α
blockers in the treatment of early PsA. No severe adverse
events were observed during the treatment period, and no
patient withdrew from the medications. This study suggests that
the TNF-α blockers can be effective in the management of
early PsA. Further controlled studies will provide more data on
this challenging topic.
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Introduction
A large body of evidences has demonstrated that the
immediate detection of inflammatory joint diseases by a rapid
referral to a rheumatologist can assure a precise diagnosis and
a tailored therapy, with a consistent advantage in prognosis
[1]. The introduction of biologic therapies for the treatment
of different forms of arthritis has profoundly modified the
clinical approach to rheumatic patients. By reducing articular
inflammation and pain, biologic therapies really contrast the
progression of joint damage.
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to increased morbidity and mortality [2]. Its early detection
with a rapid therapeutical intervention really reduces the risk
of clinical progression [3]. Unfortunately, there are many
doubts that, using a traditional clinical approach, we may
achieve early detection and treatment of PsA. In contrast
with rheumatoid arthritis (RA), PsA patients show a reduced
articular and non-articular tenderness with a threshold of
articular pain which is significantly increased [4]. On the
other hand, evidences showing that traditional disease-
modifying anti-rheumatic drugs (DMARDs) are really able
to block clinical progression of the disease are controversial
[5, 6]. In fact, despite the use of a DMARD, follow-up
shows that more than 60% of the patients starting with a
mono-oligoarthritis develop a polyarthritis, with a close
relationship between number of involved joints and disease
duration [5].
In order to evaluate the role of biologic agents in early
PsA, we designed a multicentre longitudinal observational
study (LOS) based on real clinical practice and aimed at
assessing the effectiveness and safety of the TNF-α
blockers (adalimumab, etanecept, infliximab) at present
recommended and available in the Italian market.
Patients and methods
Study design
The study was designed as a longitudinal and observational,
and it was carried out in five Italian centres, enrolling
consecutive patients affected by early PsA and attending their
follow-up visit at the PsA Early Arthritis Clinic (PsA-EAC).
PsAwas classified based on the CASPAR criteria [7].
Inclusion criteria were patient’s age >18 years, disease
duration ≤12 months and an unsatisfactory response to
previous conventional treatments carried out for at least
3 months. Unsatisfactory response was therefore deemed as
DAS28 threshold as ≥3.2.
Allpatientswerepreviouslytreatedwithnon-steroidal anti-
inflammatory drugs (NSAIDs) and with disease-modifying
anti-rheumatic drugs (DMARDs). In particular, Salazopyrin
was administered in three patients and two patients were on
leflunomide; both drugs were withdrawn for intolerance.
Methotrexate was administered in 22 patients and among
them 11 withdrew for lack of efficacy (five patients) or for
intolerance (six cases, mainly for raised liver function tests).
Finally, steroids was administered in a minimal percentage
(5/29, 17%) at a dosage ≤5 mg of prednisone.
The study protocol considered a recruitment period from
January 2008 until December 2008.
The exclusion criteria were previous usage of anti TNF-α
blockers, the usage of more than 10 mg prednisone daily,
variation of dosage of NSAIDs or prednisone within 2 weeks
of enrolment.
The choice of any of the three TNF-α blockers was
decided by the expert’s opinion, without any restriction.
However, the association with methotrexate (up to 15 mg
weekly) was allowed based on the expert’s opinion.
All patients gave their written informed consent, and the
study protocol was approved by the local ethical committees.
Patients
Twenty-nine consecutive patients with early PsA, routinely
attending the PsA-EAC at the secondary referral centres (14
males, 15 females, median age 37 years, range 20–65 years;
median duration of disease 8 months, range 1–12 months)
joined the present study protocol.
In patients eligible for therapy with TNF-α blockers the
tuberculin skin test and interferon gamma release assay
tests were carried out to screen latent tubercular infection
[8]. Patients screened positive for TB test were excluded.
After the screening, all patients were given infliximab
(IFN) at dosage of 5 mg/kg every 6–8 weeks (after the
usual start up and then increasing or decreasing the dosage
when warranted), etanercept (ETN) 50 mg weekly and
adalimumab (ADA) 40 mg eow.
Disease activity
The patients were followed up at 12 weeks and at 24 weeks.
Clinical and laboratory assessment were carried out at
baseline (T0), at 12 weeks (T1) and at 24 weeks (T2)
including: physical examination, vital signs, TJC (68 tender
joints), SJC (66 swollen joints), HAQ score and PASI, ESR
and CRP and VAS score on patient’s global assessment of
disease activity.
Moreover, the DAS28 was calculated at the beginning of
the TNF-α blockers treatment, at 12 weeks and at 24 weeks
of follow-up treatment.
Assessment of response
Effectiveness was defined as an improvement of DAS28 at
12 and 24 weeks of treatment, which was therefore
considered the main endpoint. Secondary endpoints were
an improvement of TJC, SWJ, HAQ score and PASI score.
Statistical analysis
Descriptive data were expressed, if not otherwise specified, as
median and range. Changes from baseline to the 12- and 24-
week follow-up assessments were analysed using the Wilcoxon
paired sign rank test for the endpoints considered. All statistical
procedures were two-sided at a significance level of 0.05.
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package for Windows (version 13.0; Chicago, IL).
Results
Descriptive, clinical and functional data
Main demographic and clinical characteristics of the
patients studied measured at baseline and 12 and 24 weeks
are reported in Table 1. In particular, the oligoarticular
pattern of the disease was the main subset observed (15/29,
52%). An overlap with axial involvement was observed in
nine patients (9/29, 31%), and the axial was defined by the
presence of inflammatory back pain [9]. Dactylitis and nail
involvement were recorded in 6/29 (20%), 4/29 (14%) and
5/29 (17%), respectively.
The PASI score was overall low (median, 0.6), while the
median HAQ score at the beginning was quite high. Indeed, a
remarkable improvement of HAQ was observed at 12 weeks
and with another significant improvement at 24 weeks.
Finally, biologic agents were chosen as follows: ETN in
19/29 (65.5%), ADA in 7/29 (24.1%) and IFN in 3/29
(10.4%).
Effectiveness
At baseline, median DAS28 was 5.3 (4–6.8); at 12 weeks, it
dropped to 4 (2.1–6.0) and at 24 weeks, it was 3 (0.5–5.2)
which could be considered a value in keeping with a low
disease activity status.
At 12 weeks, 16 patients (16/29, 55%) showed an
improvement of the DAS28 >1.2, six patients (6/29, 20%)
showed an improvement of DAS28 >0.6≤1.2 and seven (7/
29, 24%) had an improvement of DAS28 <0.6. In particular,
at 12 weeks, only two patients (2/29, 6.9%) still showed a
DAS28 >5.1 which reflects a high disease activity.
At 24 weeks, 24 patients (24/29, 82%) showed an
improvement of the DAS28>1.2, while one patient (1/29,
3.4%) showed an improvement of DAS28>0.6≤1.2 and
four (4/29, 14%) showed an improvement of DAS28<0.6.
Again, at 24 weeks, one patient showed a DAS28≥5.1, and
this was considered as non-responder.
Therefore, EULAR response criteria at 24 weeks were
achieved by 24 patients, four had a poor response and one
was a non-responder.
However, a statistical significant improvement of the
DAS28 at 12 and 24 weeks was observed in all patients.
Moreover, a significant improvement of the secondary
endpoints was also recorded.
In Table 2 is a summary of all data on the effectiveness.
Adverse events
Noserious adverse events were observed during the 24 weeks
of treatment with the three biologic medications. No cases of
tuberculosis or demyelinating disease were reported during
this study.
Overall (n=29) Etanercept (n=19) Adalimumab (n=7) Infliximab (n=3) p
Gender (M/F) 40 (12/15) 13/6 1/6 0/3 NS
Age, years 37 (20–65) 46 (20–65) 34 (24–62) 35 (20–43) NS
PASI 0.6 (0.0–5.2) 1 (0–5.2) 0.3 (0–1.2) 0.6 (0.2–2.0) NS
HAQ 1 (0.5–2.6) 1 (0.5–2.6) 1.37 (0.5–1.6) 0.62 (0.6–1.6) NS
Tender joints 8 (5–18) 8 (5–18) 6 (5–16) 8 (7–18) NS
Swollen joints 3 (1–12) 3 (1–12) 3 (1–5) 2 (1–4) NS
Table 1 Demographic, baseline
clinical and therapeutic charac-
teristics of patients
Values are median (range) or
absolute frequency
M male, F female, NS not
significant
Endpoints T0 (range) T12 (range) T24 (range) p
DAS 28 5.3 (4–6.8) 4 (2.1–6.0) 3 (0.5–5.21) <0.001
Tender joints count 8 (5–18) 5 (1–15) 2 (0–10) <0.001
Swollen joints counts 3 (1–12) 1 (0–4) 0.5 (0–4) <0.001
PASI 0.6 (0–5.2) 0.3 (0–4.5) 0.2 (0–2.1) <0.001
HAQ 1 (0.5–2.62) 0.37 (0.1–2.2) 0.25 (0–1.75) <0.001
ESR 24 (3–65) 15 (2–86) 9 (2–25) <0.001
CRP 1.5 (0–36) 0.6 (0–11) 0.3 (0–12) <0.001
Patients’ VAS 70 (50–90) 50 (30–70) 35 (0–90) <0.001
Table 2 Summarized data on
the effectiveness
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The innovation of biological therapies has transformed the
treatment and care of many different forms of arthritis,
including RA, ankylosing spondylitis, PsA and juvenile
arthritis. The current biological therapies profoundly reduce
the pain and inhibit the progression of joint damage for
these chronic and debilitating diseases [10, 11].These
complex therapies prevent disability, and these compounds
are life-altering treatment for many patients. However, for
some patients, access to these therapies is limited or non-
existent due to their cost and availability.
To date, the use of biologic therapies in patients with early
PsA has not been reported in randomized controlled trial, or
from real clinical practice. Moreover, conventional agents are
partially effective in established PsA but, in general, trails with
DMARDS have not included validated outcome measures for
the different manifestations of PsA [12]. However, an early
intervention could also modify the whole spectrum of
psoriatic disease, including extra-articular manifestations [13].
The present study, designed as LOS in five centres, showed
a preliminary data on the positive effectiveness of the TNF-α
blockersasadrugclass,aspreviouslyreported[14]. In fact, all
three medications, freely chosen by the experts, demonstrated
to modify significantly the disease activity. In particular, the
results also showed that an early intervention positively
changed the patient’s function as demonstrated by the rapid
improvement of the HAQ, the median HAQ score at the
beginning was quite high; in fact, the median HAQ score at
the beginning was quite high reflecting the activity status
more than the severity of the disease.
Moreover, the PASI score was overall low which is in
keeping with PsA patients attending the rheumatology
outpatient clinics. Another interesting point is the disease
durationoftheenrolledpatientswhichwaslessthan12months
and, therefore, in a real early stage of the natural course of the
disease. A low disease activity status was reached at 24 weeks
in the majority of the patients, as deemed by the DAS28,
confirming that in a relatively short period of time, it is
possibletogainawellclinicalcontrolofthedisease.Moreover
a DAS28 <2.6 was observed in nine patients (31%) indicating
a disease remission status as previously defined [15].
The choice of DAS28 as main outcome measure was
based on some evidences that it resulted as the most
responsive and discriminative instrument [16] as well as it
was considered as an outcome measure for the peripheral
joint involvement in PsA patients [17].
Recently, the British Society for Rheumatology Biologics
Register (BSRBR) published the results form the largest
longitudinal observation study on PsA patients and the
DAS28 (EULAR response criteria) was deemed as the
response criteria to the biologic agents [15]. They showed that
at 6 months of treatment, 75.8% of the population studied (n=
596) were EULAR responder. Our data are slightly different
with a trend toward a higher percentage (82%) but similar to
some extent. However, our sample was absolutely smaller
than the BSRBR, and it was focused on early PsA patients.
Therefore, the present study needs to be confirmed in a
larger sample of patients in the early stages of the disease,
probably recruited from a study designed as a multicentre,
international based on the real clinical practice. Alterna-
tively, results from registries could be also useful on this
intriguing topic. In fact, in our study, the concomitant stable
use of MTX was allowed (but was not an inclusion
criterion) and then some patients were also on MTX (11/
29, data not shown). We did not found any differences (data
not shown), and these data could be biassed by the small
number of patients studied even if, to some extent, these
data were already reported [18].
In some ways, this study also confirms that the response
to TNF-α blockers in psoriatic patients is greater than that
observed in RA patients, as shown by the BSRBR [19].
Also, the present study showed that the biologic agents can
effectively act on both major components of the psoriatic
disease, even if the skin involvement was minimal in our
group.
A major point against the wide usage of TNF-α blockers
in early stages of the disease could be the high costs of
these medications. However, a cost-effectiveness study on
established PsA has been published by us, confirming that
even in late stage of the disease, a therapeutical intervention
was effective [20].
In conclusion, the present study showed that an early
intervention in PsA patients with a short disease duration is
really effective and it should be the real treatment approach.
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